| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
188,370,000 |
| Market
Cap: |
16.70(B) |
| Last
Volume: |
1,778,607 |
Avg
Vol: |
1,398,026 |
| 52
Week Range: |
$76.22 - $99 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Other |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 811 |
| Guru Rank Value : 0.9 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile BioMarin Pharmaceutical is a biotechnology company that develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Co.'s commercial products are Aldurazyme (laronidase) for Mucopolysaccharidosis I; Brineura (cerliponase alfa) for the treatment of late infantile neuronal ceroid lipofuscinosis type 2; Kuvan (sapropterin dihydrochloride) for the treatment of phenylketonuria; Naglazyme (galsulfase) the treatment of Mucopolysaccharidosis VI ; Palynziq (pegvaliase-pqpz) for adult patients with phenylketonuria; and Vimizim (elosulfase alpha) for the treatment of Mucopolysaccharidosis IV Type A.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
3,625 |
| Total Buy Value |
$0 |
$0 |
$0 |
$314,469 |
| Total People Bought |
0 |
0 |
0 |
1 |
| Total Buy Transactions |
0 |
0 |
0 |
1 |
| Total Shares Sold |
159,588 |
261,929 |
319,053 |
656,089 |
| Total Sell Value |
$13,270,852 |
$22,448,451 |
$27,661,182 |
$61,420,002 |
| Total People Sold |
5 |
6 |
7 |
7 |
| Total Sell Transactions |
10 |
20 |
27 |
56 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Meier Richard A |
Director |
– • – |
2024-06-03 |
4 |
D |
$76.41 |
$416,511 |
D/D |
(5,451) |
120,776 |
|
- |
|
| Meier Richard A |
Director |
– • – |
2024-06-03 |
4 |
OE |
$63.10 |
$416,460 |
D/D |
6,600 |
126,227 |
|
- |
|
| Heron Elaine J |
Director |
– • – |
2024-06-03 |
4 |
D |
$76.41 |
$318,477 |
D/D |
(4,168) |
97,720 |
|
- |
|
| Heron Elaine J |
Director |
– • – |
2024-06-03 |
4 |
OE |
$63.10 |
$318,466 |
D/D |
5,047 |
101,888 |
|
- |
|
| Mueller Brian |
EVP, Chief Financial Officer |
• – – |
2024-05-30 |
4 |
AS |
$75.19 |
$375,950 |
D/D |
(5,000) |
72,159 |
|
- |
|
| Mueller Brian |
EVP, Chief Financial Officer |
• – – |
2024-05-30 |
4 |
OE |
$63.10 |
$315,500 |
D/D |
5,000 |
77,159 |
|
- |
|
| Davis George Eric |
EVP, Chief Legal Officer |
• – – |
2024-05-28 |
4 |
AS |
$74.46 |
$3,043,802 |
D/D |
(40,850) |
56,157 |
|
- |
|
| Davis George Eric |
EVP, Chief Legal Officer |
• – – |
2024-05-28 |
4 |
OE |
$63.10 |
$2,577,635 |
D/D |
40,850 |
97,007 |
|
- |
|
| Anderson Elizabeth M |
Director |
– • – |
2024-05-21 |
4 |
A |
$0.00 |
$0 |
D/D |
4,720 |
27,800 |
|
- |
|
| Meier Richard A |
Director |
– • – |
2024-05-21 |
4 |
A |
$0.00 |
$0 |
D/D |
7,080 |
119,627 |
|
- |
|
| Hombach Robert J. |
Director |
– • – |
2024-05-21 |
4 |
A |
$0.00 |
$0 |
D/D |
4,720 |
35,220 |
|
- |
|
| Ho Maykin |
Director |
– • – |
2024-05-21 |
4 |
A |
$0.00 |
$0 |
D/D |
4,720 |
21,360 |
|
- |
|
| Heron Elaine J |
Director |
– • – |
2024-05-21 |
4 |
A |
$0.00 |
$0 |
D/D |
4,720 |
96,841 |
|
- |
|
| Countouriotis Athena |
Director |
– • – |
2024-05-21 |
4 |
A |
$0.00 |
$0 |
D/D |
4,720 |
6,900 |
|
- |
|
| Pyott David E I |
Director |
– • – |
2024-05-21 |
4 |
A |
$0.00 |
$0 |
D/D |
4,720 |
49,750 |
|
- |
|
| Bodem Barbara W. |
Director |
– • – |
2024-05-21 |
4 |
A |
$0.00 |
$0 |
D/D |
4,720 |
6,900 |
|
- |
|
| Enyedy Mark J |
Director |
– • – |
2024-05-21 |
4 |
A |
$0.00 |
$0 |
D/D |
4,720 |
6,900 |
|
- |
|
| Dere Willard H |
Director |
– • – |
2024-05-21 |
4 |
A |
$0.00 |
$0 |
D/D |
4,720 |
32,300 |
|
- |
|
| Hubbard Cristin |
EVP, Chief Commercial Officer |
• – – |
2024-05-20 |
4 |
A |
$0.00 |
$0 |
D/D |
19,390 |
19,390 |
|
- |
|
| Bienaime Jean Jacques |
Director |
– • – |
2024-05-20 |
4 |
D |
$77.05 |
$92,614 |
D/D |
(1,202) |
473,792 |
|
- |
|
| Burkhart Erin |
GVP, Chief Accounting Officer |
• – – |
2024-05-17 |
4 |
D |
$76.97 |
$76,431 |
D/D |
(993) |
15,163 |
|
- |
|
| Bienaime Jean Jacques |
Director |
– • – |
2024-05-10 |
4 |
AS |
$81.14 |
$1,622,800 |
D/D |
(20,000) |
474,994 |
|
- |
|
| Bienaime Jean Jacques |
Director |
– • – |
2024-05-10 |
4 |
OE |
$63.10 |
$1,262,000 |
D/D |
20,000 |
494,994 |
|
- |
|
| Bienaime Jean Jacques |
Director |
– • – |
2024-05-09 |
4 |
AS |
$81.62 |
$1,632,400 |
D/D |
(20,000) |
474,994 |
|
- |
|
| Bienaime Jean Jacques |
Director |
– • – |
2024-05-09 |
4 |
OE |
$63.10 |
$1,262,000 |
D/D |
20,000 |
494,994 |
|
- |
|
1285 Records found
|
|
Page 1 of 52 |
|
|
1.44 (1.6%) 
